# Intralesional Injection of Acyclovir Versus Candida Antigen in Treatment of Plantar Warts

> **NCT05429151** · PHASE4 · UNKNOWN · sponsor: **Sohag University** · enrollment: 40 (estimated)

## Conditions studied

- Acyclovir and Candida Antigen in Treatment of Plantar Wart

## Interventions

- **DRUG:** Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd andcandida antigen

## Key facts

- **NCT ID:** NCT05429151
- **Lead sponsor:** Sohag University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-13
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-05-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429151, "Intralesional Injection of Acyclovir Versus Candida Antigen in Treatment of Plantar Warts". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05429151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*